structured RNAs and amplify short RNA templates. The research “has extended the capabilities of RNA to RNA polymerization in ways that have not been achieved before,” said Scott Silverman of the ...

Chimeron Bio aims to transform RNA therapy with its novel nanoparticle technology by developing new vaccines and therapies based on self-amplifying RNA for the treatment of infectious diseases ...

First, the kit enables the user to amplify the mRNA and convert it to cDNA directly from a cell lysate, with no loss of RNA. Second, the linear RNA amplification step improves the sensitivity of ...

Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA ...

The decision follows a recent recommendation from the European Medicines Agency’s human medicines committee and makes Kostaive the first self-amplifying messenger RNA (mRNA) COVID-19 vaccine to be ...

including circular RNA, self-amplifying RNA and beyond from discovery to clinic and towards scalable manufacturing, unlocking the huge therapeutic and commercial potential of this emerging class ...

Maternal hepatitis C virus (HCV) RNA titer > 10⁶ International Units (IU)/mL and antepartum bleeding are key predictors of perinatal transmission, with the risk ranging from 1.5% to 28.5%.

Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA ...

Unlike standard mRNA vaccines, self-amplifying mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response. About CSL CSL (ASX: CSL; USOTC: CSLLY) is a global ...

today announced that the European Commission has granted marketing authorization for KOSTAIVE® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is ...